Recombinant Anti-FGFR1 antibody [EPR806Y] - Low endotoxin, Azide free (ab206382)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR806Y] to FGFR1 - Low endotoxin, Azide free
- Suitable for: IP, WB, ICC/IF
- Knockout validated
- Reacts with: Human
Overview
-
Product name
Anti-FGFR1 antibody [EPR806Y] - Low endotoxin, Azide free
See all FGFR1 primary antibodies -
Description
Rabbit monoclonal [EPR806Y] to FGFR1 - Low endotoxin, Azide free -
Host species
Rabbit -
Tested applications
Suitable for: IP, WB, ICC/IFmore details
Unsuitable for: IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: SH-SY5Y cell lysate.
-
General notes
ab206382 is the carrier-free version of ab76464.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.20
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR806Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab206382 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 92 kDa.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
Notes |
---|
IP
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. Predicted molecular weight: 92 kDa. |
ICC/IF
Use at an assay dependent concentration. |
Target
-
Function
Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF). -
Tissue specificity
Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells. -
Involvement in disease
Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsBinding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor. -
Cellular localization
Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle - Information by UniProt
-
Database links
- Entrez Gene: 2260 Human
- Omim: 136350 Human
- SwissProt: P11362 Human
- Unigene: 264887 Human
-
Alternative names
- Basic fibroblast growth factor receptor 1 antibody
- bFGF-R-1 antibody
- BFGFR antibody
see all
Images
-
This WB data was generated using the same anti-FGFR1 antibody clone [EPR806Y] in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (cat# ab76464).
Lane 1: Wild type HAP1 whole cell lysate (20 µg)
Lane 2: FGFR1 knockout HAP1 whole cell lysate (20 µg)
Lane 3: MCF7 whole cell lysate (20 µg)
Lane 4: SH-SY5Y whole cell lysate (20 µg)Lanes 1 - 4: Merged signal (red and green). Green - ab76464 observed at 140 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab76464 was shown to specifically react with FGFR1 when FGFR1 knockout samples were used. Wild-type and FGFR1 knockout samples were subjected to SDS-PAGE. ab76464 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1 µg/mL and 1/10000 dilution respectively. Blots were developed with 800CW Goat anti Rabbit and 680CW Goat anti Mouse secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
-
ab76464 (purified) at 1/500 immunoprecipitating FGFR1 in 10 μg A-204 (Human muscle rhabdomyosarcoma)whole cell lysate (Lanes 1 and 2, observed at 145 kDa). Lane 3 - Rabbit monoclonal IgG (ab172730) instead of ab76464 in A-204 whole cell lysate. For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Blocking/Dilution buffer and concentration: 5% NFDM/TBST.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab76464).
Protocols
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (3)
ab206382 has been referenced in 3 publications.
- Zhang J et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602-12 (2013). WB . PubMed: 23583981
- Zhang J et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 18:6658-67 (2012). PubMed: 23082000
- Tomlinson DC & Knowles MA Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 177:2379-86 (2010). PubMed: 20889570